Dr. Noubar B. Afeyan is an Independent Director at Rubius Therapeutics, Inc., a Chairman at ModernaTX, Inc., a Chairman at Moderna, Inc., a Founder & CEO at Flagship Pioneering, a Chairman at Omega Therapeutics, Inc., a Chairman at Repertoire Immune Medicines, Inc., a Chairman at Tessera Therapeutics, Inc., a Manager at Flagship Ventures Fund IV LP and a Manager at Flagship Ventures Fund IV-RX LP.

He is on the Board of Directors at Sana Biotechnology, Inc., Massachusetts Institute of Technology, IDEA Foundation, Rubius Therapeutics, Inc., Ameriabank CJSC, Boston Symphony Orchestra, Inc., LS Dissolution, Inc., Armenia 2020, Armenian General Benevolent Union, Cobalt Biomedicine, Inc., Cogen Immune Medicine, Inc., Dilijan International School of Armenia, Epiva Biosciences, Inc. and Ring Therapeutics, Inc. Dr. Afeyan was previously employed as a Chairman by Evelo Biosciences, Inc., a Co-Founder by Indigo Agriculture, Inc., a Lead Independent Director by Seres Therapeutics, Inc., a Chairman by Axcella Health, Inc., an Independent Director by Eleven Biotherapeutics, Inc., an Independent Director by BIND Therapeutics, Inc., a Chairman by Joule Unlimited Technologies, Inc., a Chairman by Theracrine, Inc., a Chairman by Codon Devices, Inc., a Lead Independent Director by Helicos Biosciences Corp., a Co-Founder by Epitome Biosystems, Inc., an Independent Non-Executive Director by BG Medicine, Inc., a Chief Business Officer & Senior Vice President by Applera Corp., a Co-Founder by Celera Genomics Group, a Chairman by ChemGenics Pharmaceuticals, Inc., a Chairman & Chief Executive Officer by PerSeptive Biosystems, Inc.,He received his undergraduate degree from McGill University and a doctorate degree from Massachusetts Institute of Technology.